MEFTAL-SPAS® Tablet
MEFTAL-SPAS® is a balanced antispasmodic and analgesic formulation indicated for the symptomatic relief of smooth muscle spasms and associated visceral pain.
Clinical Applications
Most popular clinical applications:
More Clinical Application
Prescribing Guidelines by Age
MEFTAL-SPAS® product range is formulated to provide age-appropriate dosing across the patient lifecycle. While the tablet is the primary form for adults and adolescents, the brand provides specialised delivery systems for younger demographics.
| Patient Age Group | Recommended Format | Typical Clinical Use |
|---|---|---|
| Infants (up to 6 months) | Drops | Infantile colic and gastric distress. |
| Children (6 months - 12 years) | Suspension | Pediatric abdominal pain and bloating. |
| Adolescents (12+ years) | Tablet | Monthly period pain and functional GI spasms. |
| Adults | Tablet | Biliary, Renal, and Intestinal colic. |
| Adults (Acute Care) | Injection | Severe, sudden spasms requiring rapid onset. |
Pharmacological Highlights for the Physician
-
Dual Mechanism :
Combines the anticholinergic effect of Dicyclomine HCl (to stop the spasm) with the anti-prostaglandin effect of Mefenamic Acid (to stop the pain). -
Rapid Absorption :
Optimized for quick onset, typically providing relief within 30 to 60 minutes. -
Proven Safety :
Established clinical profile with over three decades of trusted use in the Indian healthcare ecosystem.
Prescribing Information
Generic Name
Mefenamic Acid and Dicyclomine Hydrochloride Tablets IP
(Brand Name: MEFTAL-SPAS ® Tablets / MEFTAL-SPAS ®; DS Tablets)
Qualitative and Quantitative Composition
MEFTAL-SPAS® Tablets
Each uncoated tablet contains:
Mefenamic Acid IP - 250 mg
Dicyclomine Hydrochloride IP - 10 mg
Colour: Tartrazine.
MEFTAL-SPAS® DS Tablets
Each uncoated tablet contains:
Mefenamic Acid IP - 500 mg
Dicyclomine Hydrochloride IP - 20 mg
Colour: Tartrazine.
Dosage Form and Strength
Dosage Form: Tablets.
Dosage Strength: Mefenamic acid 250 mg / 500 mg + dicyclomine hydrochloride 10 mg / 20 mg per tablet respectively.
Posology and Method of Administration
For oral administration in adults and adolescents.
-
MEFTAL-SPAS® Tablets
1 to 2 tablets to be administered three times daily.
-
MEFTAL-SPAS® DS Tablets
1 tablet to be administered three times daily.
Treatment is generally required till the time dysmenorrhea symptoms persist i.e., 3 to 5 days during the menses. MEFTAL-SPAS® / MEFTAL-SPAS® DS Tablets should be taken preferably with or after food. Or, as prescribed by the physician.
Contraindications
MEFTAL-SPAS® / MEFTAL-SPAS® DS Tablets are contraindicated in the following
- Known hypersensitivity to mefenamic acid or to dicyclomine or to any component of the formulation.
- Pre-existing asthma and aspirin-sensitive asthma.
- Active ulceration/bleeding or chronic inflammation of upper or lower gastrointestinal (GI) tract.
- Treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
- Pre-existing renal disease/obstructive uropathy.
- Glaucoma.
- Myasthenia gravis.
- Last trimester of pregnancy.
- Lactation.
- Inflammatory bowel disease, paralytic ileus and intestinal atony.
Possible Side Effects (Safety Information)
For detailed quantitative, and qualitative composition, therapeutic indications, posology and method of administration, contraindications, special warnings and precautions for use, drug interactions, undesirable effects, overdose, mechanism of action, pharmacodynamic properties of MEFTAL-SPAS® Tablets, MEFTAL-SPAS® DS Tablets, download the note.